Cashu | Summary | CTMX

HomeWatchlistNewsSignalsPicks

DJI

+0.78%

SPX

+0.70%

IXIC

+0.52%

FTSE

+0.59%

N225

0.00%

AXJO

+0.56%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Overview

Join our newsletter to keep up to date with us!

Key Stats

Market Cap

162.60M

Dividend Yield

0.00%

P/E Ratio

3.91

EPS

0.39

Revenue

138.10M

Avg. Volume

1.98M

About

What does CTMX do?

CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.

Sector

💻 Health Care

IPO

CEO

Employees

Headquarters

California, USA

Website

http://www.cytomx.com

Recently from Cashu

CytomX Therapeutics: Leading the Charge in Innovative Cancer Treatment with Probody Technology

CytomX Therapeutics: Pioneering Cancer Care with Innovative Probody Technology

Stocks

Health Care

ctmx

CytomX Therapeutics

CTMX

+0.01 (+0.50%)

2.01

USD

At close at May 16, 20:41 UTC